Lorlatinib Outperforms Crizotinib in NSCLC
- PMID: 33298467
- DOI: 10.1158/2159-8290.CD-NB2020-110
Lorlatinib Outperforms Crizotinib in NSCLC
Abstract
The CROWN study suggests that lorlatinib is effective in patients newly diagnosed with advanced ALK-positive non-small cell lung cancer. In the phase III trial, patients treated with lorlatinib were twice as likely to be alive without disease progression after 1 year than those who received crizotinib-with slower progression of brain metastases.
©2020 American Association for Cancer Research.
Comment on
-
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
